Benzion Blech1, Amaal J Starling2. 1. Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA. blech.benzion@mayo.edu. 2. Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA.
Abstract
PURPOSE OF REVIEW: The past two decades has seen an influx of noninvasive neuromodulation devices aimed at treatment of various primary headache disorders, including cluster headache and migraine. This narrative review is to summarize the current options in noninvasive neuromodulation in migraine. RECENT FINDINGS: A variety of noninvasive neuromodulation devices have been FDA cleared and marketed for use in migraine, including single-pulse transcranial magnetic stimulation (sTMS), noninvasive vagal nerve stimulators (nVNS), and external trigeminal nerve stimulators (eTNS). Newer devices include peripheral electrical stimulation devices (PES), caloric stimulation, and others. Each has varying levels of evidence supporting its use in migraine, tolerability profiles, and access issues. Noninvasive neuromodulation devices can be beneficial when used in patients with migraine, with minimal side effects. As more devices are developed, approved, and marketed in the future, rigorous research on efficacy and safety remain a top priority.
PURPOSE OF REVIEW: The past two decades has seen an influx of noninvasive neuromodulation devices aimed at treatment of various primary headache disorders, including cluster headache and migraine. This narrative review is to summarize the current options in noninvasive neuromodulation in migraine. RECENT FINDINGS: A variety of noninvasive neuromodulation devices have been FDA cleared and marketed for use in migraine, including single-pulse transcranial magnetic stimulation (sTMS), noninvasive vagal nerve stimulators (nVNS), and external trigeminal nerve stimulators (eTNS). Newer devices include peripheral electrical stimulation devices (PES), caloric stimulation, and others. Each has varying levels of evidence supporting its use in migraine, tolerability profiles, and access issues. Noninvasive neuromodulation devices can be beneficial when used in patients with migraine, with minimal side effects. As more devices are developed, approved, and marketed in the future, rigorous research on efficacy and safety remain a top priority.
Authors: Dawn C Buse; Elizabeth W Loder; Jennifer A Gorman; Walter F Stewart; Michael L Reed; Kristina M Fanning; Daniel Serrano; Richard B Lipton Journal: Headache Date: 2013-06-28 Impact factor: 5.887
Authors: Richard B Lipton; David W Dodick; Jessica Ailani; Kaifeng Lu; Michelle Finnegan; Armin Szegedi; Joel M Trugman Journal: JAMA Date: 2019-11-19 Impact factor: 56.272
Authors: David L Nelson; Lee A Phebus; Kirk W Johnson; David B Wainscott; Marlene L Cohen; David O Calligaro; Yao-Chang Xu Journal: Cephalalgia Date: 2010-06-15 Impact factor: 6.292
Authors: Anna P Andreou; Philip R Holland; Simon Akerman; Oliver Summ; Joe Fredrick; Peter J Goadsby Journal: Brain Date: 2016-05-30 Impact factor: 13.501
Authors: David W Dodick; Richard B Lipton; Jessica Ailani; Rashmi B Halker Singh; Anand R Shewale; Sihui Zhao; Joel M Trugman; Sung Yun Yu; Hema N Viswanathan Journal: Headache Date: 2020-02-19 Impact factor: 5.887
Authors: Bernice Kuca; Stephen D Silberstein; Linda Wietecha; Paul H Berg; Gregory Dozier; Richard B Lipton Journal: Neurology Date: 2018-11-16 Impact factor: 9.910
Authors: Stephen T Foldes; Amanda R Jensen; Austin Jacobson; Sarah Vassall; Emily Foldes; Ann Guthery; Danni Brown; Todd Levine; William James Tyler; Richard E Frye Journal: J Pers Med Date: 2021-12-06